NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

Core Insights - NeuroSense Therapeutics announced promising findings from its Phase 2b PARADIGM clinical trial, highlighting the significant impact of its investigational therapy PrimeC on microRNA modulation in ALS patients [1][2] Group 1: Clinical Trial Findings - The PARADIGM trial demonstrated a consistent downregulation of 161 mature miRNAs in ALS patients treated with PrimeC, with no significant changes in the placebo group, indicating PrimeC's targeted biological activity [3] - PrimeC treatment resulted in the downregulation of ALS-related miRNAs, specifically miR-199 and miR-181, which are associated with disease progression and survival, correlating with reported improvements in clinical function [4][7] Group 2: Research Collaboration and Presentation - The research was conducted in collaboration with Prof. Noam Shomron from Tel Aviv University, a leader in microRNA research, and presented by Dr. Jeffrey Rosenfeld at the 77th Annual American Academy of Neurology Meeting [5][6] Group 3: Mechanistic Insights and Future Development - NeuroSense aims to deepen mechanistic insights and identify miRNA-based biomarkers for treatment response, with the Phase 2b data providing a foundation for further investigations into PrimeC's impact on miRNA maturation and relevance in other neurodegenerative diseases [6] Group 4: About ALS and PrimeC - ALS is an incurable neurodegenerative disease with a significant annual burden of $1 billion in the U.S., affecting over 5,000 people annually, and is expected to grow by 24% by 2040 [9] - PrimeC is a novel extended-release oral formulation combining two FDA-approved drugs, designed to target multiple mechanisms of ALS, and has shown efficacy in reducing functional and respiratory deterioration [10]